2026年6月2日，广州白云山医药集团股份有限公司（股票名称：白云山）发布2026年5月股份变动月报表。报告期为2026年5月1日至5月31日。公告显示，公司法定/注册股本合计约16.26亿元（RMB 1,625,790,949），期内未有任何新增发行、购回、注销或库藏股活动，整体股本结构保持不变。
根据公告，截至本月底，公司H股（代码：00874）维持2.199亿股（219,900,000股），A股仍为14.0589亿股（1,405,890,949股），两者合计与上月保持一致。公告同时披露，期内未有股权激励计划或期权变动，也未涉及任何其他股份变动事项。公司确认遵守香港联交所《上市规则》及相关法律规定。本次月报由公司秘书黄雪贞签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.